Shahzad Raza
Overview
Explore the profile of Shahzad Raza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
787
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, et al.
Blood Adv
. 2025 Mar;
PMID: 40088469
No abstract available.
2.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Mar;
:JCO2500453.
PMID: 40053892
No abstract available.
3.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401730.
PMID: 39965175
Purpose: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety,...
4.
Jaberi-Douraki M, Xu X, Dima D, Ailawadhi S, Anwer F, Mazzoni S, et al.
Blood Cancer J
. 2024 Dec;
14(1):223.
PMID: 39706832
Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosomal material leading to uncontrolled proliferation in the bone marrow. Ethnic and racial...
5.
Merz M, Dima D, Hashmi H, Ahmed N, Stolzel F, Holderried T, et al.
Blood Cancer J
. 2024 Dec;
14(1):214.
PMID: 39632797
Despite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies...
6.
Lytvynova O, Jwayyed J, Pastel D, Prasad R, Khouri J, Williams L, et al.
Antibodies (Basel)
. 2024 Oct;
13(4).
PMID: 39449322
Multiple myeloma (MM) is a hematological malignancy and poses significant therapeutic challenges. This review synthesizes evidence from pivotal clinical trials to guide induction treatment for transplant-eligible (TE), newly diagnosed MM...
7.
Paul B, Anwer F, Raza S, Mammadzadeh A, Khasawneh B, Shatnawi S, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272795
The use of 4-drug induction regimens for treatment naïve newly diagnosed multiple myeloma (NDMM) is associated with improved depth of response and progression-free survival (PFS). However, head-to-head trials of 4-drug...
8.
Parekh D, Tiger Y, Jamouss K, Hassani J, Zerdan M, Raza S
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272790
Multiple myeloma is a heterogeneous condition characterized by the proliferation of monoclonal B-cells, for which there is currently no curative treatment available. Relapses are, unfortunately, common after first-line treatment. While...
9.
Dima D, Hughes M, Orland M, Ullah F, Goel U, Anwer F, et al.
Amyloid
. 2024 Jul;
31(3):195-201.
PMID: 38956891
Background: Daratumumab's incorporation in the upfront treatment of light chain (AL) amyloidosis has led to daratumumab (dara) refractoriness early in disease course. Patients who experience relapse or have suboptimal response...
10.
Lin C, Tariq M, Ullah F, Sannareddy A, Khalid F, Abbas H, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892379
Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites. Common manifestations of MM include anemia, renal...